Fast Five Quiz: Idiopathic Pulmonary Fibrosis: Management and Treatment

Elwyn C. Cabebe, MD


October 17, 2023

Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease of unknown etiology, characterized by progressive lung scarring. Global incidence and prevalence of IPF range between 0.09 and 1.30 per 10,000 people, and it affects more than 3 million people worldwide. Patients are primarily older than age 60 years. IPF is the most common interstitial lung disease among middle-aged and older adults. Although the cause of IPF is unknown, risk factors include a history of smoking, family history, and genetic predispositions. The clinical course is variable. Progressive deterioration in lung function results in increasing dyspnea, chronic cough, and frequent hospitalizations. The prognosis is poor and no cure has been found, with a reported median survival of 3-5 years from diagnosis. Treatment is typically more effective in the early stages of disease, making early recognition important to achieving improved outcomes.

Are you up-to-date on the management and treatment options available to patients at different stages of IPF? Test yourself with a quick quiz.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.